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Abstract
Background: STAT3 signaling plays the pivotal role in tumorigenesis through EZH2 epigenetic modification, which
enhanced STAT3 activity by increased tyrosine phosphorylation of STAT3. Here, another possible feedback
mechanism and clinical significance of EZH2 and STAT3 were investigated in gastric cancer (GC).
Methods: STAT3, p-STAT3 (Tyr 705) and EZH2 expression were examined in 63 GC specimens with matched normal
tissues by IHC staining. EZH2 and STAT3 were also identified in five GC cell lines using RT-PCR and western blot
analyses. p-STAT3 protein was detected by western blotting. In order to investigate whether EZH2 expression was
directly regulated by STAT3, EZH2 expression was further detected using siRNA for STAT3 or IL-6 stimulation, with
dual luciferase reporter analyses, electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation
(ChIP) assays. The clinical significance of STAT3, p-STAT3 and EZH2 expression was evaluated by multi-factor COX
regression and Kaplan-Meier analyses.
Results: Hyper-activation of STAT3, p-STAT3 and EZH2 expression were observed in GC cells and tissues. STAT3
signaling was correlated with EZH2 expression in GC (R = 0.373, P = 0.003), which was consistent with our data
showing that STAT3 as the transcriptional factor enhanced EZH2 transcriptional activity by binding the relative
promoter region (-214 ~ -206). STAT3 was an independent signature for poor survival (P = 0.002). Patients with
STAT3+/EZH2+ or p-STAT3+/EZH2+ had a worse outcome than others (P < 0.001); Besides, high levels of STAT3 and
EZH2 was associated with advanced TNM staging (P = 0.017). Moreover, treatment with a combination of siSTAT3
and EZH2-specific inhibitor, 3-deazaneplanocin A (DZNEP), increased the apoptotic ratio of cells. It is benefit for
targeting STAT3-EZH2 interplay in GC treatment.
Conclusions: Our results indicate that STAT3 status mediated EZH2 upregulation, associated with advanced TNM
stage and poor prognosis, suggesting that combination with knockdown of STAT3 and EZH2 inhibitor might be a
novel therapy in GC treatment. Collectively, STAT3, p-STAT3 and EZH2 expression were provided for the precision
medicine in GC patients.
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Background
Although the prevalence of gastric cancer (GC) has
gradually decreased, it still accounts for a large portion
of cancer-related deaths in China [1]. One of the most
informative prognostic factors is the tumor stage, which
involves both the depth of invasion and extent of metas-
tasis. The size and histologic type of a tumor may also
be useful factors in prognostication [2]. Despite the
complexity of gastric tumorigenesis, several molecular
studies have identified novel prognostic biomarkers.
Consequently, many efforts have been made to identify
and validate novel biomarkers that are not only useful
for predicting prognosis and patient survival, but also
for predicting the tumor response to specific anticancer
drugs [3–5]. Signal transducer and activator of transcrip-
tion 3 (STAT3) or enhancer of zeste homologue 2
(EZH2) is the potential molecular biomarker for tumor
progression and mainly serve as the poor predictor of
outcome [6–9].
Many recent studies have suggested that inflammation
plays an important role in the development of GC. Aber-
rant IL-6/STAT3 signaling in cancer cells have emerged
as a major mechanism for cancer initiation and develop-
ment [10, 11]. IL-6 induces STAT3 activation, leading to
cell proliferation and malignancy [9, 12, 13]. Upon acti-
vation, it is mostly involved in carcinogenesis [13, 14].
Judd et al. reported that mice with STAT3 hyperactiva-
tion developed GC in association with chronic gastritis
[15]. However, it still remains unclear how constitutive
activated STAT3 in GC development.
IL-6/STAT3 signaling plays an important role in
regulating epigenetic aberrance during tumorigenesis,
especially in the expression of certain key epigenetic
enzymes, such as EZH2 [16]. EZH2, also called histone
lysine methyltransferase (HKMT), was cloned as a gene
belonging to the polycomb group of genes, which epige-
netically silences the expression of some tumor suppressor
genes (TSGs) [17]. It has been shown to be abundantly
expressed in various malignancies with poor prognosis,
including gastric, prostate, breast, and bladder cancers,
and hematologic malignancies [6, 18–22]. Knockdown of
EZH2 by siRNA has been demonstrated to inhibit breast
cancer cell proliferation, whereas pharmacological inhib-
ition of EZH2 results in the apoptosis of breast cancer
cells, but not normal cells [23]. Recently, EZH2 binds to
and methylates STAT3, leading to enhanced STAT3 ac-
tivity by increasing tyrosine phosphorylation of STAT3
[24, 25]. The specific EZH2 inhibitor reverses the silencing
of polycomb target genes and diminishes STAT3 activity.
EZH2 has been shown to directly interact with and regulate
the activity of the following DNA methyltransferases
(DNMTs): DNMT1, DNMT3a, and DNMT3b [26, 27].
DNMTs transfer a methyl group from S-adenosylmethio
nine to the 5′-position of cytosine in CpG dinucleotides
present in gene promoters, thereby maintaining a consist-
ent pattern of epigenetic gene silencing of TSGs in cancer
cells [28].
Although the genes methylated in cancer cells are pack-
aged along with nucleosomes containing 3Me H3H27-
marked genes, which are silenced in cancer, they have
been shown to be independent of promoter DNA methy-
lation, thus highlighting that 3Me H3K27 could poten-
tially be an independent mechanism for silencing TSGs
[29]. DNA methylation and transcriptional silencing of
cancer genes have been shown to persist, despite the
depletion of EZH2 [30], suggesting that simultaneously
inhibiting EZH2 would be more effective in reversing
3Me H3K27 and DNA methylation [31]. Today, 3-
deazaneplanocin A (DZNep) was reported to decrease
the expression levels of the polycomb repressive com-
plex 2 (PRC2) in cancer cells, where loss of the 3Me
H3K27 marked derepression of epigenetically silenced
targets [32–36]. Moreover, DZNep is a novel inhibitor
of histone methyltransferase EZH2 [32, 35, 37, 38].
Previous studies have shown that increased EZH2 is
involved in the pathology of gastrointestinal inflammation
and associated cancers [39]. Moreover, EZH2 serves as an
anti-apoptotic factor in GC development during IL-6/
STAT3 activation. Taken together, it is tempting to specu-
late that EZH2 may be a target of STAT3 and mediate the
functions of IL-6/STAT3 signaling. Until now, there is no
report the potential interaction between STAT3 signaling
and EZH2 during GC development. Hence, we will
explore the relationship between STAT3 and EZH2 as well
as other clinicopathological features in GC.
Results
Co-expression of STAT3 and EZH2 in GC cell lines and
primary GCs
IL-6/STAT3 signaling plays a critical role in carcinogen-
esis by regulating various genes. EZH2, a protein that epi-
genetically silences tumor suppressor genes, was induced
by IL-6 stimulation. To determine the inner relationship
between STAT3 and EZH2, we first analyzed mRNA and
protein expression levels of STAT3 and EZH2 in five GC
cell lines using RT-PCR and real-time PCR (Fig. 1a,
Additional file 1: Figure S5 and S6) and western blot ana-
lyses (Fig. 1b), respectively. All five GC cell lines expressed
high STAT3 and EZH2 mRNA and protein levels. Both
mRNA and protein levels were higher in SGC7901 cell
lines than those in AGS, BGC823, MGC803, and
MKN45 cell lines. Western blot analyses revealed two
immunoreactive signals, an 85-kDa for STAT3 and an
86-kDa for EZH2.
The levels of STAT3, p-STAT3 and EZH2 expression
in GC tissues and their corresponding non-cancerous
gastric mucosa were analyzed by Western blot. The
levels of STAT3 status and EZH2 expression in GC were
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Fig. 1 Hyperactivation of STAT3, p-STAT3 and EZH2 was associated with poor survival in the GC cohort. a Differential expression of STAT3 and
EZH2 mRNA was detected in GC cells using RT-PCR. b Differential expression of STAT3, p-STAT3 and EZH2 in GC cells using Western Blotting. c
Co-expression of STAT3 status and EZH2 protein was detected in GC and matched normal tissues using Western Blotting; d High or low levels of
STAT3 status and EZH2 expression in GC and adjacent normal tissues using IHC staining; p-STAT3 and EZH2 showed a focal or diffuse pattern in
the nuclei (200 × magnification). Kaplan-Meier analyses show the effect of STAT3 (e), EZH2 (f), p-STAT3 expression (g), or the combination
between STAT3 and EZH2 expression (h) in overall survival
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higher than those in normal tissues (Fig. 1c). IHC stain-
ing showed that higher level of STAT3 expression in GC
tissues (43/63, 68.2%) than that in the corresponding
normal tissues (24/63, 38.1%, P = 0.003; Table 1 and
Fig. 1d). Intense nuclear staining was observed for EZH2
in GC (Fig. 1d). As shown in Table 1, the protein expres-
sion of EZH2 in the nuclei of GC tissues was signifi-
cantly higher (47/63; 74.6%) than those in normal tissues
(21/63, 33.3%, P = 0.001). A close correlation between
STAT3 and EZH2 was observed in the cohort by χ2-test
(Spearman rank correlation coefficient = 0.373, P = 0.003;
Fig. 1d; Additional file 1: Table S2).
Co-expression of STAT3 and EZH2 correlated with poor
survival in GC patients
A significantly elevated expression of STAT3 and EZH2
was noted in 43 (68.2%) and 47 (74.6%) cases, respect-
ively. Furthermore, 82.5% (52/63) of the patients were
either EZH2+ and/or STAT3+, of which 35 (55.6%)
showed a combined positivity for STAT3 and EZH2
(Additional file 1: Table S2). Notably, more than half
the patients belonged to the high-expression group.
Univariate analysis demonstrated that high expression of
EZH2 was significantly associated with poor survival (P =
0.001, log-rank; Fig. 1f). In multivariate Cox-regression
analyses, STAT3 was a significant independent predictor
of survival (HR: 7.535; 95% CIs: 2.104 ~ 26.993; P = 0.002;
Additional file 1: Table S4). In contrast, EZH2 was not an
independent factor in GC prognosis (HR: 0.863; 95% CIs:
0.337 ~ 2.204; P = 0.757; Additional file 1: Table S4).
Further supporting these results, the overall survival
(OS) rate was significantly correlated with STAT3 pro-
tein expression. In this cohort, the 5-year OS rate was
31.6%. As expected, the OS was significantly higher in
the STAT3− group than in the STAT3+ group (P = 0.025,
log-rank test; Fig. 1e). The OS of pSTAT3− group was
also better than pSTAT3+ group (P = 0.002, log-rank test;
Fig. 1g). Furthermore, it was observed that OS was bet-
ter in the STAT3−/EZH2− group than in other groups.
In particular, the 5-year OS rate was significantly lower
in STAT3+/EZH2+ patients (22.3%) than in STAT3
−/EZH2− patients (52.4%, P < 0.001). Additionally, pa-
tients with EZH2+/STAT3+ expression had poorer prog-
nosis than those with either EZH2− and/or STAT3−
expression (P = 0.007, log-rank; Fig. 1h). Similar results
were shown in the combination between p-STAT3 and
EZH2 expression (Additional file 1: Figure S3).
Therefore, these results indicate that STAT3 and
EZH2 are important genetic markers in predicting a
poor prognosis for GC patients undergoing resection.
Thus, our findings highlight the value of EZH2 as a pre-
dictor of survival that could be more significant when
considered in conjunction with STAT3 in GC.
Co-expression of STAT3 and EZH2 correlated with TNM
stage in GC
In addition, most of GC samples exhibited coexpression
of STAT3 and EZH2 in the cohort (Fig. 1c). Further-
more, the association of STAT3 and EZH2 immunohisto-
chemical expression levels with clinicopathological features
was evaluated in 63 GC samples (Table 2). STAT3 expres-
sion in GC tissues was found to be significantly associated
with patients’ age (P = 0.024), TNM stage (P = 0.0001), and
lymph node metastasis (P = 0.016), and EZH2 expression
was positively correlated with patients’ gender (P = 0.043)
and TNM stage (P = 0.002). The present study showed that
hyperactivation of STAT3 and EZH2 in GC tissues was
significantly associated with advanced TNM stage. Notably,
40% of GC tissues, corresponding to TNM stages I and II,
and 65.7% of GC tissues, corresponding to TNM stages III
& IV, showed a significantly high expression of both
STAT3 and EZH2 (Additional file 1: Table S3, P = 0.017).
STAT3 signaling enhances EZH2 promoter activity in GC cells
Given the co-expression of STAT3 and EZH2 in GC, we
investigated whether STAT3 could regulate the expres-
sion of EZH2; thus, we analyzed EZH2 expression at
both mRNA and protein levels in SGC7901 cells trans-
fected with three pairs of siSTAT3 primers and scram-
bled negative control siRNA. Interestingly, STAT3
siRNAs decreased the level of STAT3 and EZH2 expres-
sion (Fig. 2a and b, Additional file 1: Figure S4). And the
high levels of STAT3 and EZH2 were induced by IL-6
stimulation (Fig. 2c), subsequently, siRNA of STAT3 after
IL-6 addition, the luciferase reporter was reduced at the
original level of background (Fig. 2e). Our results indicated
that EZH2 was a potential target gene of STAT3 signaling.
We performed transient expression studies in order to
explore the effect of STAT3 signaling on EZH2 pro-
moter activity. The level of EZH2 promoter activity in
siSTAT3-treated SGC7901 cells was found to be signifi-
cantly lower than that in the untreated control. The rela-
tive activity of EZH2 was decreased by siSTAT3 (P =
0.0248), but it was increased to 6.18-fold by IL-6 stimu-
lation (P = 0.0035; Fig. 2e). Combined siRNA for STAT3
with IL-6 addition, decreased activity of EZH2 promoter
luciferase reporter was detected apparently compared
with IL-6 stimulation alone in SGC7901 cells. Our study




EZH2 expression STAT3 expression
Low/- (%) High/+ (%) Low/- (%) High/+ (%)
Tumor 63 16 (25.3) 47 (74.6) 20 (31.7) 43 (68.2)
Normal 63 42 (66.7) 21 (33.3) 39 (61.9) 24 (38.1)
EZH2, P = 0.001; STAT3, P = 0.003
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highlights the potential interplay that STAT3 signaling
promotes EZH2 expression in GC cells.
We had also performed a detailed analysis of the
EZH2 promoter in the NCBI database, and identified
that it contained three conserved STAT3-binding sites at
the main promoter region of EZH2 gene (Additional
file 1: Figure S1). STAT3 binds to two known sequences,
HIS and GAS, to exert its anti-apoptotic and oncogenic
effects. These sites contain the canonical STAT3-binding
motifs TTC(N)2-4GAA or TT(N)4-6AA [40]. Hence, we
determined that the STAT3-responsive elements are
present in the EZH2 promoter at position −346 to +52,
which, in turn, corresponds to the consensus STAT3-
binding site TTN(4-6)AA. Corroborating these findings,
the results of our study demonstrated a significant de-
crease in luciferase activity for the shorter length EZH2
promoter gene (−436 to +52), as compared to that of the
full length EZH2 promoter (−1702 to +52; Fig. 2d, P =
0.024; Additional file 1: Figure S1), indicating that the pro-
moter region between −436 and +52 is critical for EZH2
promoter activation in response to STAT3. This fragment
contains the 3 STAT3-binding motifs described above.
Subsequently, we performed ChIP-PCR analysis using
SGC7901 cells to determine the precise consensus se-
quences for EZH2 promoter activation and to further in-
vestigate the role of the promoter fragment −436 to +52
containing three motifs of STAT3. Furthermore, in order
to confirm that STAT3 bound to the EZH2 specific pro-
moter_(-436– + 52), we used a ChIP-PCR procedure,
comprising 33 PCR cycles optimized to achieve amplifi-
cation of DNA that had been precipitated with STAT3.
In the absence or presence of siSTAT3 after IL-6 stimu-
lation or not, the enrichment of STAT3-binding to
EZH2 fragments was decreased after knocking down of
STAT3 by PCR and quantitative real-time PCR analyses
(Fig. 2f, Additional file 1: Figure S7), coinciding with the
downregulation of EZH2 expression at mRNA and pro-
tein levels (Fig. 2a, and b). Our results demonstrated
that STAT3 was recruited to EZH2 promoter region at
the main three STAT3-binding motifs, which indicates
that EZH2 transcription is required for STAT3-binding
enrichment.
Three STAT3 cis-element sequences, STAT3-1, STAT3-
2 and STAT3-3, were located at different regions of the
EZH2 main promoter. To further confirm the effect of
STAT3 fragments on the transcriptional activity of EZH2
promoter, four vectors were constructed, including vector
p373 (Fragment 1) containing the three Stat3-binding
fragments, vector p222 (Fragment 2) lacking the Stat3-1
fragment, vector p163 (Fragment 3) lacking both Stat3-1
and STAT3-2 fragments, and vector p131 (Fragment 4),
which has no Stat3-fragment (Additional file 1: Figure S2).
Table 2 Correlation between EZH2, STAT3 and clinicopathologic features in GC
Characteristics Cases
n
EZH2 expression P-value STAT3 expression P-value
Low/- High/+ Low/- High/+
Age (y) ≤60 22 6 16 0.804 11 11 0.024
> 60 41 10 31 9 32
Gender Male 47 15 32 0.043 17 30 0.200
Female 16 1 15 3 13
Differentiation Well 11 5 6 0.164 3 8 0.658
Moderate 13 4 9 3 10
Poor 39 7 32 14 25
Borrmann’s pathologic classification Ulceration 47 10 37 0.342 15 32 0.678
Prominence 7 2 5 3 4
Diffuse 9 4 5 2 7
Tumor Location Antrum 45 11 34 0.785 14 31 0.865
Body & Cardia 18 5 13 6 12
TNM stage I 12 8 4 0.002 10 2 0.0001
II 13 4 9 3 10
III 27 3 24 7 20
IV 11 1 10 0 11
Lymph node metastasis No 30 12 18 0.051 14 16 0.016
Yes 33 4 29 6 27
Distant metastasis No 53 13 40 0.738 18 35 0.388
Yes 10 3 7 2 8
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Fig. 2 EZH2 is a potential downstream target of STAT3 signaling. a EZH2 mRNA expression was decreased in SGC7901 cells transfected with
siSTAT3. b The protein level of EZH2 expression was downregulated in SGC7901 cells using knockdown of STAT3 with siRNA. c The expression of
STAT3 status and EZH2 was induced by IL-6 in SGC7901 cells. d Luciferase activity was measured in extracts from SGC7901 cells transfected with
different luciferase reporter constructs, containing the full-length promoter (Region 1) or the region only containing STAT3-binding sites (Region
3) or not (Region 2); luciferase activity normalized for Renilla luciferase activity and expressed relative to the activity of the untreated group; the
higher activity of EZH2 was detected in Region 1 and Region 3, which contained STAT3-binding sites (Fig. 2d, P < 0.001). e Dual luciferase reporter
analysis of EZH2 promoter. The construct with full-length of EZH2 promoter (-1702/+52) was inactivated by siSTAT3 treatment with or without IL-
6 stimulation. f The specific region (−436/+48) of EZH2 promoter was detected by ChIP-PCR. STAT3 mediated fold-enrichment of STAT3-binding
regions of EZH2 promoter. Further, the binding activity was increased by IL-6 stimulation compared with the untreated group (P = 0.0059). When
knockdown of STAT3 using siRNA, the binding activity was decreased with or without IL-6 (P = 0.0043). g The nuclear extracts from SGC7901 cells
were incubated with biotin-labeled wild-type before the mutant or cold probes were added for 20 min. The specific region of the STAT3 stand
motif (−222/−197) demonstrated effective binding ability. All the results for EZH2 activity were analyzed by EMSA. The results in (d) and (e) are
represented as mean ± SD values
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Transfection of p373 (Fragment 1) and p222 (Fragment 2)
led to an increase in luciferase activity compared with the
transfection of p163 (Fragment 3) and p131 (Fragment 4),
especially, the luciferase activities of Fragment 1 and
Fragment 2 were higher than Fragment 3 and 4 (Fragment
1: 4.67 ± 0.56; Fragment 2: 4.86 ± 0.68; Fragment 3: 1.12 ±
0.27; Fragment 4: 0.74 ± 0.16; P = 0.0063; Additional file 1:
Figure S2). And there was no obvious different between
Fragment 1 and 2 for the EZH2 luciferase activity (P =
0.094; Additional file 1: Figure S2). It means that the
second Stat3 motif was important for regulation of EZH2.
These data narrowed the enhancer activity to the -222 bp
to -163 bp region, and suggested that this Stat3-binding
region contained a cis-acting element that interacted with
STAT3 to induce transcription.
To investigate which Stat3 motif region binding to
EZH2 promoter, an EMSA was performed using syn-
thetic 26-bp oligo-nucleotides containing the Stat3-
binding fragment (Additional file 1: Table S1). We exam-
ined the binding activity of the nuclear extract to candi-
date nucleotide sequences in order to identify the
STAT3-responsive element. Several possible permuta-
tions of the STAT3-binding site were also systematically
synthesized and tested for their ability to bind activated
STAT3. The results showed that STAT3 enhanced the
binding activity of nuclear extracts to the probe (con-
taining Stat3 motif ). The synthesized mutant sequences
were found to show little or no binding to activated
STAT3. Further experiments with the wild-type probe,
without biotin modification, which “cold-competed” in
the EMSA assay, demonstrated a significant decrease in
the STAT3 target-binding capacity in vivo (Fig. 2g), it
indicated that stat3-binding site located in the -214 bp
to -206 bp region, played the important role in the
transcriptional activity of EZH2 gene.
Anti-apoptotic activity of STAT3-mediated EZH2 in GC cells
Aberrant expression of STAT3 is known to contribute
to malignancy [12]. In the present study, inhibition of
STAT3 signaling by siRNA significantly increased
caspase-3/9 positivity in SGC7901 cells (Fig. 3e and f ),
suggesting that STAT3 contributes to the anti-
apoptotic effect in GC cells (Fig. 3d). We further evalu-
ated the intracellular changes in GC cells treated with
the EZH2-specific inhibitor, DZNep. We observed that
DZNep reduced the expression of EZH2, which resulted
in increased caspase-3/9 activity (Fig. 3e and f), leading to
apoptosis of SGC7901 cells (Fig. 3a, b and c). The single
agent DZNep treatment did induce G1/G0 phase arrest in
our study (Fig. 3g, P = 0.0038). Thus, our findings demon-
strate that EZH2 is the downstream target gene of STAT3
signaling and plays an important role in the anti-apoptotic
effect of the latter in GC cells.
In addition, our clinical data showed that hyperactiva-
tion of STAT3 and EZH2 occurred in GCs. Further
supporting this clinical observation, knockdown experi-
ments involving the treatment of GC cells with STAT3
siRNA in the presence of DZNep demonstrated an in-
creased apoptotic rate, as well as enhanced caspase-3/9
activity (Figs. 3e and f, P = 0.003, P = 0.027, respectively),
which in turn resulted in the down-regulation of EZH2 at
both mRNA and protein levels. We next examined cell
cycle variation and apoptosis in cells treated with siSTAT3
or DZNep alone or in combination. As shown in Fig. 3g,
cells treated with DZNep alone can induce apoptosis and
G1/G0 phase arrest; the combination of STAT3-siRNA
and DZNep induced more apoptosis than others (P < 0.05;
Fig. 3c). It will be important that these trials can measure
high-resolution DNA methylation and histone modifica-
tions in order to correlate clinical responses with candi-
date epigenetic changes.
Discussion
Several studies have suggested that STAT3 and EZH2
are closely associated with cell proliferation, invasion,
and metastasis [37–40]; our findings demonstrate that
co-expression of STAT3 and EZH2 in GC cells is associ-
ated with poor prognosis. In particular, the activation of
EZH2 and STAT3 is significantly correlated to TNM
stage and patient survival, suggesting that a combination
of STAT3 and EZH2 expression could determine clinical
TNM stage and predict disease outcome.
STAT3 is positively correlated with EZH2 expression
in GC cells and tissues. Knockdown of STAT3 resulted
in down-regulation of EZH2 at the mRNA and protein
levels. We next determined whether STAT3 could be a
transcriptional regulator of the EZH2 gene. We trans-
fected SGC7901 GC cells with a reporter vector encod-
ing luciferase under control of the EZH2 promoter.
Knockdown of STAT3 by siRNA decreased EZH2 pro-
moter activity, which was abrogated by mutation of the
STAT3 DNA-binding site in the EZH2 promoter. We
next carried out ChIP assay to assess whether STAT3
could directly bind to the EZH2 promoter. STAT3 pro-
tein binding at the EZH2 promoter was significantly
increased in SGC7901 cells, and was increased 6.18-fold
with IL-6 stimulation, which is consistent with the re-
sults of studies showing that EZH2 protein expression is
induced by IL-6 in multiple myeloma cell lines [39]. As
expected, transfecting cells with a siSTAT3 significantly
decreased luciferase reporter activity. Upon further
study, we found three STAT3 cis-element-binding sites
in the EZH2 promoter. Deletion analysis showed that
the second STAT3-binding site was active in the lucifer-
ase reporter assay following IL-6 stimulation. Mutation
of this STAT3-binding motif decreased its ability to bind
STAT3. This study demonstrates that STAT3 directly
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Fig. 3 (See legend on next page.)
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regulates EZH2 expression by binding to EZH2 pro-
moter, which is consistent with the results of the study
in CRC [41].
Furthermore, down-regulation of STAT3 promoted
apoptosis through the suppression of EZH2, and the ac-
tivated caspase-3/9 were detected. Our results further
strengthened the results of previous studies that demon-
strated an anti-apoptotic effect of EZH2 and STAT3
over-expression via the Akt/Bad/Bcl-xL apoptotic path-
way [8, 42]. The present study was first to demonstrate
an underlying mechanism involving the regulation of
EZH2 by STAT3 and to propose the existence of a posi-
tive functional loop between STAT3 and EZH2. The
functional relationship between EZH2 and STAT3 could
be the mechanism by which STAT3 regulates cell prolif-
eration. Indeed, DZNep, an EZH2-specific inhibitor,
increased apoptosis of GC cells, when combined treat-
ment with DZNep and siSTAT3 further increased the
apoptotic rates in GC cells.
In conclusion, our study identified EZH2 protein as
an important molecule downstream of STAT3, which
mediates an anti-apoptotic effect in concert with
STAT3 (Fig. 4). Our findings suggest that EZH2
possesses anti-apoptotic activity in gastric tumorigen-
esis following STAT3 activation. Further studies are
required to elucidate the detailed functional roles of
these molecules in order to exploit them as candidates
for new therapeutic targets.
Fig. 4 The possible mechanism of STAT3 in regulating EZH2 expression
(See figure on previous page.)
Fig. 3 EZH2 mediated anti-apoptotic effects in STAT3 signaling pathway. siSTAT3 and EZH2 inhibitor, DZNep, suppressed cell proliferation
through apoptosis and cell cycle arrest. a DZNep, as the specific EZH2 inhibitor, induced cell apoptosis with a dose-dependent manner
(P = 0.0064). b siSTAT3 and/or DZNep (500 nM), decreased cell viability, as determined by MTT assay (P = 0.0052). c Effects of siSTAT3
transfection and/or DZNep exposure on cell viability for 48 h by MTT assay. Decreased cell viability was clearly detected in the group
treated with DZNep and/or siSTAT3 compared with the relative negative control (DZNep vs. Vehicle (0.1% alcohol, solution for DZNep), P = 0.0183;
siSTAT3 vs. siNC, P = 0.0026, DZNep + siSTAT3 vs. Vehicle, P < 0.001; DZNep + siSTAT3 vs. siNC, P < 0.001). d The apoptotic rate was increased upon
DZNep treatment and/or siSTAT3 transfection by FITC-Annexin-V/PI staining (DZNep vs. Vehicle, P = 0.0023, siSTAT3 vs. Vehicle, P =0.0035; DZNep +
siSTAT3 vs. Vehicle, P = 0.001, respectively). e Caspase-3 activity in cells treated with SGC7901, siNC, DZNep, siSTAT3, or a combination of DZNep and
siSTAT3. The activity of caspase-3 was higher in the group treated with siSTAT3 and/or DZNep treatment than in cells treated with vehicle (DZNep vs.
Vehicle, P = 0.0056; DZNep + siSTAT3 vs. Vehicle, P = 0.0029) and siNC (siSTAT3 vs. siNC, P = 0.0215; DZNep + siSTAT3 vs. siNC, P = 0.0038). f Caspase-9
activity in cells treated with SGC7901, siNC, DZNep, siSTAT3, or a combination of DZNep and siSTAT3. The activity of caspase-9 was higher in the group
treated with siSTAT3 and/or DZNep treatment than in cells treated with vehicle (DZNep vs. Vehicle, P = 0.0033; DZNep + siSTAT3 vs. Vehicle, P = 0.0012)
and siNC (siSTAT3 vs. siNC, P = 0.0137; DZNep + siSTAT3 vs. siNC, P = 0.0214). g Cell cycle remained unchanged treated by DZNep alone in cells. All
results in (a), (b) and (c) are presented as the mean ± SD values of three assays
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Conclusion
We found that both mRNA and protein expression levels
of EZH2 were decreased by knocking down of STAT3
with siRNA in GC cells. Moreover, STAT3, the transcrip-
tional factor, induced EZH2 activation by binding to the
specific Stat3 motif of EZH2 promoter (-214 ~ -206). High
levels of EZH2, STAT3 and p-STAT3 expression were sig-
nificantly associated with poor prognosis in GC patients.
Furthermore, combined EZH2 and STAT3 or p-STAT3
was apparently associated with worse clinical outcome,
suggesting that the panel of EZH2 and STAT3 could
be served as the potential of molecular prognostic sig-
nature. Our study also found that treatment of GC
cells with STAT3-siRNA and/or the presence of EZH2
specific inhibitor, DZNep, enhanced the downregula-
tion of EZH2 expression with increasing apoptosis.
Thus, combination between siSTAT3 and EZH2 inhibi-
tors could be contributed for the potential epigenetic
therapy against GC patients.
Methods
Reagents and cell cultures
Human IL-6 was purchased from Roche (Basel,
Switzerland). Antibodies, including anti-STAT3, anti-
p-STAT3 (Tyr 705), anti-EZH2, and anti-β-actin were
obtained from Cell Signaling Technology (Beverly, MA),
Abgent (San Diego, CA), and Sigma (St Louis, MO), re-
spectively. DZNep (Cayman Chemical, Michigan) was used
as EZH2-specific inhibitor. Five human GC cell lines were
employed. The cell lines BGC823, MGC803, SGC7901
were purchased from the Cell Bank of Shanghai (Shanghai,
China). The MKN45 and AGS cell lines were purchased
from American Type Culture Collection (ATCC; South San
Francisco, CA). Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Life Technologies, Grand Island,
NY, USA) with 10% fetal bovine serum (FBS; Life Tech-
nologies) and were maintained in a humidified 5% CO2
incubator at 37 °C.
Patients and tissue specimens
The study was scrutinized and approved by the Hospital
Bioethics Committee, and patient consent was obtained
prior to the initiation of the study. The prospective study
group comprised 63 patients who had primary gastric
adenocarcinomas and underwent gastrectomy between
January and December in 2008 at the Department of
Gastroenterology Surgery, Surgical Oncology Labora-
tory, Beijing Cancer Hospital and People’s Hospital. The
inclusion criteria for the study were as follows: (a) the
patient had no concurrent diseases precluding the ad-
ministration of systemic chemotherapy, and (b) the
patient had not received preoperative radiotherapy. All
patients were followed-up prospectively for a maximum
period of 66 months. Tissue samples of GC as well as
adjacent non-cancerous (normal appearance) gastric
tissues were fixed in 10% neutral formalin, processed for
paraffin sections, and used for histopathology and im-
munohistochemistry (IHC) studies. Clinicopathological
information was obtained from medical charts, and
histopathological examination was performed according
to the 6th edition of the American Joint Committee on
Cancer System (AJCC) staging system [41, 43]. All avail-
able H&E-stained slides of the surgical specimens were
reviewed.
Immunohistochemical analysis
Formalin-fixed paraffin-embedded sections (4-μm-thick)
from samples were collected for IHC experiments.
STAT3 and EZH2 were detected using rabbit polyclonal
antibodies. Briefly, sections were incubated with rabbit
anti-STAT3 and anti-EZH2 (1:200) overnight at 4 °C.
Normal goat serum was used as a negative control. After
washing, tissue sections were treated with biotinylated
anti-rabbit secondary antibody (Santa Cruz, CA) followed
by further incubation with streptavidin-horseradish perox-
idase complex (Dako, Carpinteria, CA), and then immersed
in 3,3-diaminobenzidine, counterstained with 10% Mayer’s
hematoxylin, dehydrated, and mounted. Both nuclear and
cytoplasmic staining was observed for STAT3, while only
nuclear staining was seen for EZH2. The intensity of immu-
noreactivity was assessed for EZH2 and STAT3 as follows:
high expression, ≥ 50% cells showing intense immunoreac-
tivity; low expression, < 50% cells showing intense immu-
noreactivity. The mean percentage of positive tumor cells
was determined in at least five areas using a high-power
field microscopy. Immunopositivity was independently
evaluated by two senior pathologists.
RNA extraction, reverse transcriptional PCR and real-time
PCR analyses
Total RNA was extracted from cells by using Trizol re-
agent (Invitrogen, Life Technologies) according to the
manufacturer’s instructions. The extracted RNA was
pretreated with RNase-free DNase, and 5 μg RNA from
each sample was used for cDNA synthesis primed with
random hexamers. PCR amplification of STAT3 or
EZH2 cDNA using STAT3 or EZH2-specific primers
(Additional file 1: Table S1) was performed under the
following conditions: initial denaturation step at 95 °C
for 5 min; followed by 30 cycles consisting of denatur-
ation at 95 °C for 30 s, primer annealing at 60 °C for
30 s, primer extension at 72 °C for 30 s; and a final
extension at 72 °C for 5 min. β-actin was used as an
internal control. Furthermore, these gene expression was
running by ABI 7500 Fast Real-time PCR System
(Applied Biosystems, Carlsbad, CA, USA) with SYBR
green (TransGen Biotech Co., Ltd., Beijing, China). 1 μl
cDNA and 1 μl primers were mixed to the final volume
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of 12 μl. The final q-PCR conditions were described
briefly: a pre-denaturation at 95 °C for 20 s, followed by
40 cycles at 95 °C for 3 s and extension at 60 °C for 30 s.
The endogenous control was β-actin. Each sample was
performed in triplicate.
Western blotting
Cells were lysed in buffer containing 50 mM Tris-HCl
(pH7.4), 125 mM NaCl, 0.1% Triton-X, and 5 mM
EDTA, and treated with 1% (v/v) protease inhibitor and
1% (v/v) phosphatase inhibitor cocktail II (Sigma).
Subsequently, 50 μg total protein from each cell-lysate
was separated by SDS-PAGE, followed by electrotransfer
onto a PVDF membrane (Millipore, Billerica, MA, USA).
Rabbit polyclonal antibodies against STAT3 (1:1000
dilution) and EZH2 (1:600 dilution) were used as pri-
mary antibodies; anti-β-actin (1:10,000 dilution) was
used as a control. Horseradish peroxidase-conjugated
anti-rabbit/mouse IgG antibody (Amersham Biosciences,
Piscataway, NJ) was used as a secondary antibody. Immu-
nodetection was accomplished using enhanced chemilu-
minescence (Amersham Biosciences).
MTT assay
SGC7901 cells were seeded into 96-well culture plates,
and 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium
bromide (MTT) was added to each well containing cells
treated with DZNep and/or siRNA mimics for STAT3
(siSTAT3) from 24 to 120 h; plates were then further incu-
bated for 4 h at 37 °C. Subsequently, MTT was removed
and dimethyl sulfoxide (DMSO, Sigma) was added to the
formazan product. The absorbance was read at 490 nm/
570 nm using microplate readers (Bio-Rad 680, Life
Science, Hercules, CA, USA).
Flow cytometry analysis for apoptosis
SGC7901 cells were treated with DZNep and or siSTAT3
for 48 h, followed by harvesting, counting (1 × 106 cells)
and re-suspending in 100 μl of phosphate-buffered saline
(PBS). Afterward, 5 μl of Annexin V (1 μg/ml) (Beckman
Coulter, Fullerton, CA) was added and incubated at RT
for 15 min, then 10 μl of propidium iodide (PI, 1 μg/
ml) was added and incubated for additional 5 min at
room temperature in the dark. Finally, the cells were
subjected to flow cytometry (FCM) to measure the
apoptosis rate with an Epics-XL-MCL flow cytometer
(Beckman Coulter, USA).
Flow cytometry analysis for cell cycle
Cell cycle analysis was performed using flow cytome-
try employing a Cell Cycle Detection kit, according to
the manufacturer’s instructions (KeyGEN Biotech, Nanjing,
China). The SGC7901 cells, were treated with DZNep
(500 μM) and/or siSTAT3 mimics for 48 h. Subsequently,
the cells were sorted using a FACSCalibur (BD Biosciences,
Franklin Lakes, NJ, USA), and cell-cycle profiles were
analyzed using WinMDI v 2.9 software (Scripps Research
Institute, La Jolla, CA, USA).
Promoter and Luciferase reporter assays
Luciferase assays were performed using the Dual Luciferase
Reporter Assay System (Promega, Madison, WI, USA).
Promoter constructs for the assays were generated by
cloning the region of the human EZH2 promoter
from −1702 to +52 and inserting it between the SacI
and XhoI restriction sites of the pGL3-Basic vector (Pro-
mega). After cloning and confirmation of the nucleotides of
the EZH2 promoter by sequencing, the construct was
named EZH2-promoter-Luc (Additional file 1: Table S1).
SGC7901 cells were co-transfected with 800 ng of
EZH2-promoter-Luc and 6 ng Renilla luciferase plasmid
pRL-TK using Lipofectamine 2000 transfection reagent
(Life Technologies), with or without IL-6 treatment
(1000U/ml). Cells were also transfected with 300 ng of
siSTAT3 to inhibit STAT3 signaling (Life Technologies).
At 24 h after transfection, the cells were washed, lysed,
and evaluated sequentially for firefly luciferase and
Renilla luciferase activities (Promega) using a BD Mono-
light 3010 luminometer (BD Biosciences) or a Lumat
luminometer (LB 9507, Germany). The results obtained
were normalized for Renilla luciferase activity and
expressed relative to the activity of the untreated cell
group transfected with EZH2-promoter-Luc. Promoter
activity was reported as mean ± SD values.
Chromatin immunoprecipitation (ChIP) and quantitative
real-time PCR assay
SGC7901 parent cells or knockdown of STAT3 in cells,
followed by stimulation with or without IL-6 (1000 U/
ml), were fixed with 1% formaldehyde and lysed for
10 min at 37 °C, and sonicated to obtain sheared DNA
fragments of approximately 200 ~ 1000 bp. The chroma-
tin was then incubated and precipitated with antibodies
against the STAT3 antibody or IgG (Santa Cruz), after
which DNA-protein immunocomplexes were collected,
using protein A/G-agarose beads (Pierce Biotechnology,
Rockford, IL, USA), and treated with RNase A (Sigma)
and proteinase K (Sigma), primers were designed for
Stat3-ChIP enriched the promoter region of EZH2 gene.
Real-time PCR was performed on non-amplified Stat3,
rabbit IgG, and Input of SGC7901 cells. ChIP DNA-
enrichments was used SYBR Green Master Mix reagents
with an ABI PRISM 7900HT sequence detection system
(pre-denaturation at 95 °C for 5 min, followed 95 °C for
10 s, 60 °C for 10 s, 72 °C for 30 min, 40 cycles). The
ready-to-use primers were employed for studying tran-
scriptional regulation of EZH2 at or around its tran-
scriptional start site (TSS). The enrichment of Stat3
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motifs binding at or around the TSS of EZH2 could be
reliably detected and quantified by ChIP real-time PCR
assay or the PCR products were run on 2% agarose gel
in 1× TBE buffer.
Electrophoretic mobility shift assay (EMSA)
EMSA nuclear extracts were prepared using the Applygen
protocol (Applygen Technologies Inc., Beijing, China). For
the mobility shift assay for STAT3-DNA binding activity, a
nucleotide sequence corresponding to the 5′-flanking re-
gion of human EZH2, containing three conserved STAT3-
binding motifs, was used (Additional file 1: Figure S1). The
EMSA probe contained the second conserved STAT3-
binding motif (Additional file 1: Table S1). DNA probes
for EMSA were synthesized as oligonucleotides (Sangong,
Shanghai; Additional file 1: Table S1). The “hot probe” was
generated by labeling the 5′-end with biotin. Further-
more, we employed a “cold probe” or “mutation probe”,
which lacked 5′-biotin labeling, in the competitive
EMSA to assess the involvement of STAT3 (Additional
file 1: Table S1). SGC7901 cells were pre-treated with
or without STAT3 siRNA, and nuclear protein was
extracted as described previously.
SGC7901 cells were pre-treated with or without
siSTAT3, and nuclear protein was extracted. EMSA was
carried out with a Gel Shift assay System (Promega) in
accordance with the manufacturer’s recommendation.
Nuclear protein (10 μg) was pre-incubated in a final
volume of 15 μl of buffer containing 10 mM Tris-HCl
(pH 7.5), 1 mM MgCl2, 50 mM NaCl, 0.5 mM EDTA,
4% glycerol, 0.5 mM DTT, and 0.5 mg of poly (dI:dC)
for 10 min, and the biotin-labeled probe was added to
the mixture; samples were incubated for 20 min at room
temperature. The protein-DNA complexes were then
electrophoresed on a 7% acrylamide gel and analyzed by
autoradiography.
Apoptosis and caspase assay
Annexin V-FITC/PI analysis (BD Bioscience, Franklin
Lakes, NJ, USA) was used to measure apoptosis induc-
tion in the siSTAT3 transfected groups with or without
the EZH2 inhibitor, DZNep treatment. Harvested cells
were washed twice in buffer and resuspended at a con-
centration of 5 × 105 SGC7901 cells in 1 ml of buffer
containing at least 40 mM Ca2+. Cells were then added
to a tube containing 5 ml of fluorescent-Annexin V/PI.
Fluorescence was quantified on a Becton Dickinson
FACScan flow cytometer (BD Biosciences) for at least
10,000 events.
After cells were transfected with siSTAT3 (or scram-
bled siRNA), they were cultured for 12 h in 6-cm dishes
containing serum-free medium with or without DZNep.
The cells were washed with 1× PBS and resuspended in
lysis buffer. Caspase-3/9 activity was assessed using a
Colorimetric CaspACE™ assay System (Promega). The
lysate was mixed with Z-DEVD-pNA and Z-LEHD-pNA
in microplates according to the manufacturer’s protocol.
The plates were read at OD 405 nm.
Statistical analyses
Data were analyzed using SPSS (version 16.0; SPSS Inc.,
Chicago, IL). Statistical significance was evaluated using
chi-square (χ2) and Mann-Whitney U-tests. Spearman
rank correlation coefficients and Fisher’s exact tests were
used to assess significant associations between different
clinicopathological variables. Kaplan-Meier survival ana-
lysis, followed by the log-rank test for Pair-wise compar-
isons, was used to analyze the influence of STAT3 and
EZH2 protein expression on overall survival of GC
patients. A P-value of < 0.05 was considered significant
and exact two-sided P values are reported.
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Additional file 1: Table S1. Oligonucleotide primers for STAT3, EZH2,
β-actin, reporter gene, EMSA, and siRNA of STAT3. Table S2. Correlation
between STAT3 and EZH2 expression in GC. Table S3. STAT3 and EZH2
were associated with the clinical stage of the malignancy. Table S4.
Multivariate analysis of factors associated with OS. Figure S1. The EZH2
promoter-Luc constructs designed for this study. (A) schematic map of
the short and full-length EZH2 promoter-Luc constructs, the full length of
construct contained three important STAT3 binding motifs (-1702/+52),
the short construct (-1702/-447) didn’t contain this STAT3 binding region
(-436/+52). (B) The promoter sequence of EZH2 was located from -436 to
+52. The three STAT3-binding motifs are highlighted in blue. Figure S2.
Deletion analysis of EZH2 promoter activity. (A) Schematic maps of the
EZH2 promoter 5′-deletion constructs used as reporter plasmids. (B)
Relative luciferase activity after transient transfection of the reporter
plasmids into SGC7901 cells. The ratios between the luciferase activities
induced by each reporter vector and pRL-TK were calculated. The data
shown are means ± SE of triplicate experiments. Figure S3. Kaplan-Meier
analysis showed the combination between p-STAT3 and EZH2 expression
in overall survival of GC patients. Figure S4. Relative expression of STAT3
by knocking down with specific siRNA in SGC7901 by real-time PCR
analysis (**p < 0.01). Figure S5. Relative expression of STAT3 in GC cell
lines by real-time PCR analysis (*p < 0.05, **p < 0.01). Figure S6. Relative
expression of EZH2 in GC cell lines by real-time PCR analysis (*p < 0.05,
**p < 0.01). Figure S7. Relative enrichment of EZH2 promoter fragment
using real-time PCR analysis (*p < 0.05). (DOCX 849 kb)
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